FibroBiologics, Inc.

FibroBiologics, Inc. is a clinical-stage biotechnology company developing fibroblast-based cell therapies for chronic diseases with high unmet medical need. Its pipeline includes CYWC628, CYPS317, CYMS101 and CybroCell™, with programs aimed at wound healing, autoimmune disease, degenerative disc disease, psoriasis, certain cancers and potential longevity applications.

3.61

3.61

— FibroBiologics, Inc.
%
Lead cell therapy candidates0% Clinical and preclinical fibroblast-based therapies targeting specific diseases such as diabetic foot ulcers, psoriasis and MS.
Platform technology0% The underlying fibroblast cell platform and related intellectual property used to generate multiple product candidates.
Research and development100% Internal discovery, preclinical studies, clinical trial preparation and regulatory work for the pipeline.

FibroBiologics does not yet sell commercial products; its near-term 'customers' are clinical trial participants,...

  • Clinical trial ecosystemprimary

    Patients, investigators, CROs and CDMOs involved in running preclinical work and clinical trials for the pipeline.

  • Wound care providerssecondary

    Hospitals and wound-care clinics that would use CYWC628 if approved for diabetic foot ulcers and related wounds.

  • Specialty physicianssecondary

    Dermatologists, neurologists and other specialists who could prescribe future approved therapies for psoriasis or MS.

  • Regulatory authoritiesprimary

    FDA and other agencies that must clear INDs and approve trials and eventual commercialization.

The company is headquartered in the United States and conducts most corporate, R&D and financing activity there...

  • •United States is the corporate and regulatory base
  • •Australia is the planned site for the CYWC628 Phase 1/2 trial
  • •FDA oversight is central for CybroCell™ and U.S. development
  • •Manufacturing is outsourced to third-party CDMOs
  • •No revenue geography disclosed because the company has no product sales

FibroBiologics is focused on advancing its fibroblast platform through clinical proof-of-concept, starting with CYWC628...

01
Clinical advancement of CYWC628short-term

A successful diabetic foot ulcer trial would validate the platform and de-risk later programs.

02
Manufacturing readinessshort-term

Cell therapy supply depends on reliable CDMO execution and sterility/process control.

03
Platform expansionmedium-term

Multiple indications improve the odds that at least one program reaches commercialization.

04
Capital formationshort-term

The company has no product revenue and needs external funding to continue development.

The company is pre-revenue, has a limited operating history and depends on successful clinical development, regulatory...

critical

Going concern and funding risk

The company has incurred losses since inception and needs substantial additional capital to fund trials and operations.

Scope
All development programs
Materiality
high
high

Manufacturing and sterility risk

Cell therapy production requires tight process control; the company already experienced timeline extensions from process issues.

Scope
CYWC628 and future cell therapy supply
Materiality
high
high

Clinical development risk

Programs may fail to show safety or efficacy, which would prevent approval and commercialization.

Scope
CYWC628, CYPS317, CYMS101, CybroCell™
Materiality
high
high

Competitive displacement

Large pharma and biotech firms have greater resources and may commercialize competing therapies first.

Scope
All target indications
Materiality
medium
medium

Commercialization capability gap

The company has no sales force or distribution network and would need partners or new capabilities post-approval.

Scope
Future approved products
Materiality
medium
R&D expense recognition
Quarterly operating loss volatility
Prepaid R&D and manufacturing deposits
Timing of expense recognition
Stock-based compensation
Operating expense and net loss
Lease commitments
Cash burn and contractual obligations

Forte Biosciences, Inc.

FBRX · Pharmaceutical Preparations

Celularity Inc

CELU · Pharmaceutical Preparations

Tyra Biosciences, Inc.

TYRA · Pharmaceutical Preparations

Kairos Pharma, LTD.

KAPA · Pharmaceutical Preparations

Ocean Biomedical, Inc.

OCEA · Pharmaceutical Preparations

BriaCell Therapeutics Corp.

BCTX · Pharmaceutical Preparations

: 28/04/2026